Brief: OncoSec Medical Presents Interim Data From Ongoing Keynote-890 Study Evaluating Tavo In Combination With Keytruda
13/12/2019 13:42
Dec 13 (Reuters) - OncoSec Medical Inc ONCS.O :
* ONCOSEC MEDICAL - PRESENTS INTERIM DATA FROM ONGOING
KEYNOTE-890
STUDY EVALUATING TAVO IN COMBINATION WITH KEYTRUDA
* ONCOSEC MEDICAL - TAVO, PEMBROLIZUMAB WERE WELL
TOLERATED; ONLY
3 OF 16 PATIENTS EXPERIENCED GRADE 3 TREATMENT-RELATED ADVERSE
EVENTS WITH TREATMENT
* ONCOSEC MEDICAL - 4 OF 14 PATIENTS SHOWED RAPID TUMOR
REDUCTION
& HAD CONFIRMED PARTIAL RESPONSE BY RECIST V1.1
* ONCOSEC MEDICAL INC - ONCOSEC EXPECTS TO REPORT FULL DATA
RESULTS IN 2020 FROM KEYNOTE-890
Source text for Eikon: ID:nPn6HQYtza
Further company coverage: ONCS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on OncoSec Medical Incorporated
See all newsBrief: OncoSec Medical Inc On June 15 Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
U.S. STOCKS ON THE MOVE-Domino's, Aldeyra, MicroVision
Brief: OncoSec Medical Files Voluntary Petition For Relief Under Provisions Of Chapter 7 Of Title 11 Of United States Code
Brief: OncoSec Medical Terminates George Chi For Cause As Employee, CFO
Brief: Oncosec Medical Receives Non Compliance Notice From Nasdaq